Albouy, B <br/><br/>
[Renal cell carcinoma management and therapies in 2010].  [electronic resource] 

 -  Bulletin du cancer  2010 
 - 17-28 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1769-6917 
<br/><br/><label>Standard No.: </label>10.1684/bdc.2010.1067  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--therapeutic use<br/>Benzenesulfonates--therapeutic use<br/>Bevacizumab<br/>Carcinoma, Renal Cell--drug therapy<br/>Chemotherapy, Adjuvant<br/>Combined Modality Therapy<br/>Everolimus<br/>Humans<br/>Indoles--therapeutic use<br/>Interferons--therapeutic use<br/>Interleukin-2--therapeutic use<br/>Intracellular Signaling Peptides and Proteins--antagonists & inhibitors<br/>Kidney Neoplasms--drug therapy<br/>Metabolic Networks and Pathways--drug effects<br/>Nephrectomy<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Protein Serine-Threonine Kinases--antagonists & inhibitors<br/>Pyridines--therapeutic use<br/>Pyrroles--therapeutic use<br/>Sirolimus--analogs & derivatives<br/>Sorafenib<br/>Sunitinib<br/>TOR Serine-Threonine Kinases<br/>Vascular Endothelial Growth Factor A--metabolism